BioCentury
ARTICLE | Company News

Melinta, Menarini deal

March 10, 2017 7:37 PM UTC

Melinta granted Menarini exclusive rights to develop and commercialize oral and IV delafloxacin in 68 countries, including Europe, the Commonwealth of Independent States and Asia-Pacific, excluding Japan. Both formulations of delafloxacin are under FDA review to treat acute bacterial skin and skin structure infections (ABSSSIs), with PDUFA dates of June 19. The broad-spectrum fluoroquinolone antibiotic is known as Baxdela in the U.S. Menarini will submit an MAA to the EMA in 2H17. Melinta will receive an undisclosed upfront payment and is eligible for development, regulatory, sales based milestones and royalties...